Synonyms: ICP-192 | ICP192
Compound class:
Synthetic organic
Comment: The chemical structure for gunagratinib was obtained from WHO Proposed list 125. It mapped to PubChem CID 138734912, and from a web search it was identified as ICP-192, which is an irreversible pan-FGFR (fibroblast growth factor receptors) inhibitor that was developed by InnoCare Pharma for antitumuor potential (especially for tumours with FGF/FGFR gene aberrations). When we generated this ligand entry in August 2021, there was no published/peer reviewed report of ICP-192's pharmacology or biological activity. Phase 1 results were reported in a meeting abstract from the 2021 annual meeting of the American Society of Clinical Oncology DOI: 10.1200/JCO.2021.39.15_suppl.4092.
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
3-[2-(3,5-dimethoxyphenyl)ethynyl]-5-(methylamino)-1-[(3S)-1-prop-2-enoylpyrrolidin-3-yl]pyrazole-4-carboxamide |
International Nonproprietary Names | |
INN number | INN |
11714 | gunagratinib |
Synonyms |
ICP-192 | ICP192 |
Database Links | |
CAS Registry No. | 2211082-53-8 (source: WHO INN record) |
GtoPdb PubChem SID | 442878695 |
PubChem CID | 138734912 |
Search Google for chemical match using the InChIKey | QFUIJOBJAQBGDH-HNNXBMFYSA-N |
Search Google for chemicals with the same backbone | QFUIJOBJAQBGDH |
Search PubMed clinical trials | gunagratinib |
Search PubMed titles | gunagratinib |
Search PubMed titles/abstracts | gunagratinib |
UniChem Compound Search for chemical match using the InChIKey | QFUIJOBJAQBGDH-HNNXBMFYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | QFUIJOBJAQBGDH-HNNXBMFYSA-N |